The article reviews the evidence and extent of the excess cardiovascular risk in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and ankylosing spondylitis. RA entails nearly twice as high a standardized mortality ratio and is considered an equivalent of type 2 diabetes with regard to cardiovascular risk. The associated excess cardiovascular risk can only partly be explained by traditional risk factors, and the underlying inflammation is crucially involved in the pathogenesis.
Data obtained from patients with early RA suggest that serum triglycerides, a proxy of disease activity as markers of systemic inflammation, impaired function of apolipoprotein A-I and HDL particles, and mediating hypertension are determinants of the excess cardiovascular risk. These changes seem to be preceded by a lowering of total cholesterol and are followed in the course of the disease by immune processes typically illustrated by positivity of rheumatoid factor. Evidence is available to postulate the notion that reduced plasma lipoprotein- associated phospholipaseA2 mass or activity, mediated by diminished hydrolysis of VLDL triglycerides and of Lp(a) phospholipids, may induce reduction or altered composition of HDL particles and apoA-I dysfunction which, along with elevated plasma triglycerides, initiate and contribute to chronic inflammation.
Lifestyle modification, traditional non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors, low-dose corticosteroids, statins, tumor-necrosis-α inhibitors and, particularly, the immunosuppressive methotrexate, all have potential beneficial effects in eliciting a reduction in disease activity and cardiovascular risk. Adherence to the recent EULAR recommendations is a key in the prevention and management of cardiovascular risk among patients with rheumatic diseases.
Keywords: Anti-TNF therapy, cardiovascular diseases, disease-modifying anti-rheumatic drugs, HDL dysfunction, inflammation, lipoprotein(a), rheumatoid arthritis, syssystemic lupus erythematosus (SLE), ankylosing spondylitis, rheumatoid factor
Effects of the Disease Characteristics and the Treatment on Psychological Status in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
Current Rheumatology Reviews Ankylosing Spondylitis Among Familial Mediterranean Fever Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Tumor Necrosis Factor Blocking Therapy and Congestive Heart Failure in Patients with Inflammatory Rheumatic Disorders: A Systematic Review
Current Medicinal Chemistry HLA-B27 and B27-Subtypes in the Pathogenesis of Ankylosing Spondylitis
Current Rheumatology Reviews Biologics in Inflammatory and Immunomediated Arthritis
Current Pharmaceutical Biotechnology Assessment of Thyroid Disorders and Autoimmunity in Patients with Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Antagonizing IL-6 in Ankylosing Spondylitis: A Short Review
Inflammation & Allergy - Drug Targets (Discontinued) The Association Between Genes and SpA in Asian
Current Rheumatology Reviews The Prevalence and Significance of Uveitis in Ankylosing Spondylitis and Other Spondyloarthropathies
Current Rheumatology Reviews Recent Advances in the Chemistry of Phthalimide Analogues and their Therapeutic Potential
Mini-Reviews in Medicinal Chemistry Early Diagnosis of AS or Other SpA - From Clinical and Radiologic Viewpoint
Current Rheumatology Reviews Periodontal Pathogens are Likely to be Responsible for the Development of Ankylosing Spondylitis
Current Rheumatology Reviews HLA and Non-HLA Genes in Ankylosing Spondylitis and Seronegative Spondyloarthritis in Asia
Current Rheumatology Reviews Inflammatory Arthritis and Heart Disease
Current Pharmaceutical Design Can We Extrapolate Data from One Immune-Mediated Inflammatory Disease to Another One?
Current Medicinal Chemistry A Proposed Serum Calprotectin IgG Cut-Off Level for Diagnosing Inflammatory Arthritis
Current Rheumatology Reviews Inhibitors of TACE and Caspase-1 As Anti-inflammatory Drugs
Current Medicinal Chemistry Which Biomarker is Useful to Evaluate as a Treatment Outcome in Spondyloarthritis?
Current Rheumatology Reviews The Immunobiology of HLA-B27: Variations on a Theme
Current Molecular Medicine Physiotherapy for Ankylosing Spondylitis: Systematic Review and a Proposed Rehabilitation Protocol
Current Rheumatology Reviews